Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer.
This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,500 participants in 1 patient group
Loading...
Central trial contact
Aurélie Abou Lovergne; Antoine ITALIANO, MD-PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal